XtalPi Holdings Files Prospectus: AI-Driven Drug Discovery Platform Reports Strong FY2025 Growth Amid Strategic Partnerships

XtalPi is a drug R&D service platform that secured U.S. safety clearance for an oral peptide and advanced a cancer drug into the Investigational New Drug (IND) application phase; however, neither contributes to revenue, which is primarily derived from its service business.

Fiscal year 2025 revenue reached RMB 802.6 million, a year-on-year increase of 201%; net profit was RMB 134.6 million (RMB 258.2 million on an adjusted basis). As of December 2025, cash reserves amounted to RMB 7.07 billion (approximately USD 1 billion).

The upfront economic benefits of the $6 billion collaboration agreement with DuoXi Biologics remain uncertain; $70 million has been received, with the remainder contingent upon R&D and regulatory milestones, as well as royalty payments based on net product sales. Tensotide peptide has obtained FDA GRAS certification, broadening business channels but not generating direct revenue.

The stock price is approximately HK$8.75, with a market capitalization of around HK$35 billion (US$4.5 billion) and a price-to-sales ratio of about 50x. The average analyst target price ranges from HK$11.45 to HK$11.60, implying a 30% upside potential from the current level.

Key concerns include whether the contract research organization (CRO) business can sustain over 100% growth in fiscal year 2026 without relying on one-time milestone payments. If revenue growth slows to 40–50% and cash reserves are depleted, the high price-to-sales ratio will face downward pressure. Should operating cash flow turn negative again in 2026, the profitability inflection point may prove to be a one-off event. The critical factor is whether the company can consistently generate rapid profits to support its current valuation.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express